Search

everythinglearnresearchcommunity

for

Search:↓

The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.

New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.

Men with benign prostate hyperplasia have more meibomian gland loss and tear film problems.

Medicines called 5-alpha-reductase inhibitors, like finasteride and dutasteride, are useful for treating enlarged prostate and male pattern hair loss.

Androgens increase norepinephrine release, promoting smooth muscle growth in male sex organs, which may contribute to benign prostatic hypertrophy.

Male pattern baldness may be an early sign of noncancerous prostate enlargement.

5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.

5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.

Many patients with lower urinary tract symptoms also have undiagnosed erectile dysfunction, which improves with treatment.

Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.

Men with early balding may have a higher risk of prostate issues, and surgery for prostate cancer has a slight survival benefit over radiation.

Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.

The conclusion is that doctors should be careful when prescribing 5α-reductase inhibitors due to possible serious side effects, and they should discuss these risks with patients.

Finasteride for hair loss lowers PSA levels, so PSA values need adjusting when screening for prostate cancer.

Urologists should screen for mental health issues before and during finasteride treatment.

Finasteride is linked to sexual dysfunction, especially in younger men using it for hair loss.

Finasteride alone increases suicide risk, but combining it with other treatments reduces this risk.

Young patients using finasteride may have higher risks of anxiety, depression, and suicidal thoughts.

Finasteride use is strongly linked to sexual dysfunction, especially in young men treating hair loss.

Finasteride use is linked to a higher risk of obstructive sleep apnea.

Physalis peruviana extract is more effective in treating benign prostatic hyperplasia in rats than finasteride and terazosine.

Dutasteride and finasteride don't raise erectile dysfunction risk.

Hair loss is linked to higher prostate-specific antigen levels and urinary symptoms, likely due to age.

Early hair loss in men could be a sign of non-cancerous prostate enlargement, and treating hair loss early might help prevent prostate issues later.

Hair loss can be an early sign of prostate enlargement.

People with early-onset hair loss (AGA) have a higher risk of heart disease, metabolic syndrome, and prostate enlargement.

Large prostate patients more likely to have hair loss.

Androgen-modulating drugs do not significantly change the heat sensitivity of prostate cancer cells.

Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.

Treatments for enlarged prostate can cause problems with ejaculation, and less invasive options might preserve sexual function better.